Display Settings:

Format

Send to:

Choose Destination

    Drug Alcohol Depend. 2006 Jun 28;83(2):174-80. Epub 2005 Dec 15.

    One year outcomes for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS).

    Teesson M, Ross J, Darke S, Lynskey M, Ali R, Ritter A, Cooke R.

    National Drug and Alcohol Research Centre, University of New South Wales, NSW, Australia. m.teesson@unsw.edu.au

    AIM: To determine 1 year outcomes for drug use, criminality, psychopathology and injection-related health problems in those entering treatment for heroin dependence in Australia. DESIGN: Longitudinal prospective cohort study. PARTICIPANTS: Seven hundred and forty five individuals entering treatment (methadone/buprenorphine maintenance therapy; detoxification; residential rehabilitation) and 80 heroin users not seeking treatment. SETTING: Sydney, Melbourne and Adelaide, Australia. FINDINGS: A total of 657 individuals were re-interviewed at 1 year, 80% of the original sample. There were substantial reductions in heroin and other drug use across all three treatment modalities. The majority of those who had entered treatment were heroin abstinent at 1 year (maintenance therapy 65%, detoxification 52%, residential rehabilitation 63%) compared to 25% of the non-treatment sample. The reduction in heroin use among the treatment samples was paralleled by reductions in poly drug use. There were also substantial reductions in risk-taking, crime and injection-related health problems across all treatment groups, and less marked reductions among the non-treatment group. Psychopathology was dramatically reduced among the treatment modalities, while remaining stable among the non-treatment group. Positive outcomes at 1 year were associated with a greater number of cumulative treatment days experienced over the 1 year follow-up period ('treatment dose') and fewer treatment episodes undertaken in that time ('treatment stability'). CONCLUSIONS: At 1 year, there were impressive reductions in drug use, criminality, psychopathology and injection-related health problems following treatment exposure. The positive findings were associated with a greater "dose" of treatment, and with more treatment stability over the follow-up period.

    PMID: 16343809 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read Click here to read Click here to read

    Patient drug information

    • Methadone (Dolophine®, Methadose®, Methadose® Oral Concentrate)

      Methadone is used to relieve moderate to severe pain that has not been relieved by non-narcotic pain relievers. It also is used to prevent withdrawal symptoms in patients who were addicted to opiate drugs and are enrolle...